Redefining the role of doxorubicin for the treatment of children with hepatoblastoma

Marcio Malogolowkin, Howard M. Katzenstein, Mark Krailo, Zhengjia Chen, John J. Quinn, Marleta Reynolds, Jorge A. Ortega

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Purpose: Systemic chemotherapy has improved the survival of patients with hepatoblastoma (HB). INT-0098 Intergroup Liver Tumor Study demonstrated that patients with HB treated with either cisplatin/fluorouracil/vincristine (CFV) or cisplatin/doxorubicin (CD) had a similar survival. The Children's Oncology Group adopted the less toxic CFV as the standard regimen for treating HB. However, international cooperative groups still favor the CD combination. We therefore decided to revisit the role of doxorubicin for the treatment of HB. Methods: Outcomes of patients with HB on the INT-0098 study were reviewed with an emphasis on the postevent survival time for both regimens to elucidate the role of doxorubicin in their retrieval. Results: Sixty-four of the 173 randomly assigned patients had an event. Of these, 55 experienced progression or recurrence after initial treatment. Eleven (31%) of 36 patients treated with CFV were successfully retrieved with a doxorubicin-containing regimen and surgery and remain alive at last contact, whereas only one (6%) of 18 patients treated with CD was alive after retrieval therapy. Conclusion: CFV is effective for stage I or II HB. Doxorubicin can be omitted as part of initial therapy in the majority of these patients, potentially limiting the long-term cardiac toxicities, without compromising outcome. Doxorubicin is effective in rescuing patients with recurrent disease after CFV and should be incorporated as a means of intensifying initial therapy for advanced-stage, nonmetastatic HB. Outcome of patients with metastatic disease at diagnosis is poor, and improving their survival will require new therapeutic approaches.

Original languageEnglish (US)
Pages (from-to)2379-2383
Number of pages5
JournalJournal of Clinical Oncology
Volume26
Issue number14
DOIs
StatePublished - Sep 15 2008
Externally publishedYes

Fingerprint

Hepatoblastoma
Doxorubicin
Cisplatin
Vincristine
Fluorouracil
Therapeutics
Survival
Poisons
Recurrence
Drug Therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Malogolowkin, M., Katzenstein, H. M., Krailo, M., Chen, Z., Quinn, J. J., Reynolds, M., & Ortega, J. A. (2008). Redefining the role of doxorubicin for the treatment of children with hepatoblastoma. Journal of Clinical Oncology, 26(14), 2379-2383. https://doi.org/10.1200/JCO.2006.09.7204

Redefining the role of doxorubicin for the treatment of children with hepatoblastoma. / Malogolowkin, Marcio; Katzenstein, Howard M.; Krailo, Mark; Chen, Zhengjia; Quinn, John J.; Reynolds, Marleta; Ortega, Jorge A.

In: Journal of Clinical Oncology, Vol. 26, No. 14, 15.09.2008, p. 2379-2383.

Research output: Contribution to journalArticle

Malogolowkin, M, Katzenstein, HM, Krailo, M, Chen, Z, Quinn, JJ, Reynolds, M & Ortega, JA 2008, 'Redefining the role of doxorubicin for the treatment of children with hepatoblastoma', Journal of Clinical Oncology, vol. 26, no. 14, pp. 2379-2383. https://doi.org/10.1200/JCO.2006.09.7204
Malogolowkin, Marcio ; Katzenstein, Howard M. ; Krailo, Mark ; Chen, Zhengjia ; Quinn, John J. ; Reynolds, Marleta ; Ortega, Jorge A. / Redefining the role of doxorubicin for the treatment of children with hepatoblastoma. In: Journal of Clinical Oncology. 2008 ; Vol. 26, No. 14. pp. 2379-2383.
@article{8f0576245c6244beaf7e8735d446a077,
title = "Redefining the role of doxorubicin for the treatment of children with hepatoblastoma",
abstract = "Purpose: Systemic chemotherapy has improved the survival of patients with hepatoblastoma (HB). INT-0098 Intergroup Liver Tumor Study demonstrated that patients with HB treated with either cisplatin/fluorouracil/vincristine (CFV) or cisplatin/doxorubicin (CD) had a similar survival. The Children's Oncology Group adopted the less toxic CFV as the standard regimen for treating HB. However, international cooperative groups still favor the CD combination. We therefore decided to revisit the role of doxorubicin for the treatment of HB. Methods: Outcomes of patients with HB on the INT-0098 study were reviewed with an emphasis on the postevent survival time for both regimens to elucidate the role of doxorubicin in their retrieval. Results: Sixty-four of the 173 randomly assigned patients had an event. Of these, 55 experienced progression or recurrence after initial treatment. Eleven (31{\%}) of 36 patients treated with CFV were successfully retrieved with a doxorubicin-containing regimen and surgery and remain alive at last contact, whereas only one (6{\%}) of 18 patients treated with CD was alive after retrieval therapy. Conclusion: CFV is effective for stage I or II HB. Doxorubicin can be omitted as part of initial therapy in the majority of these patients, potentially limiting the long-term cardiac toxicities, without compromising outcome. Doxorubicin is effective in rescuing patients with recurrent disease after CFV and should be incorporated as a means of intensifying initial therapy for advanced-stage, nonmetastatic HB. Outcome of patients with metastatic disease at diagnosis is poor, and improving their survival will require new therapeutic approaches.",
author = "Marcio Malogolowkin and Katzenstein, {Howard M.} and Mark Krailo and Zhengjia Chen and Quinn, {John J.} and Marleta Reynolds and Ortega, {Jorge A.}",
year = "2008",
month = "9",
day = "15",
doi = "10.1200/JCO.2006.09.7204",
language = "English (US)",
volume = "26",
pages = "2379--2383",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "14",

}

TY - JOUR

T1 - Redefining the role of doxorubicin for the treatment of children with hepatoblastoma

AU - Malogolowkin, Marcio

AU - Katzenstein, Howard M.

AU - Krailo, Mark

AU - Chen, Zhengjia

AU - Quinn, John J.

AU - Reynolds, Marleta

AU - Ortega, Jorge A.

PY - 2008/9/15

Y1 - 2008/9/15

N2 - Purpose: Systemic chemotherapy has improved the survival of patients with hepatoblastoma (HB). INT-0098 Intergroup Liver Tumor Study demonstrated that patients with HB treated with either cisplatin/fluorouracil/vincristine (CFV) or cisplatin/doxorubicin (CD) had a similar survival. The Children's Oncology Group adopted the less toxic CFV as the standard regimen for treating HB. However, international cooperative groups still favor the CD combination. We therefore decided to revisit the role of doxorubicin for the treatment of HB. Methods: Outcomes of patients with HB on the INT-0098 study were reviewed with an emphasis on the postevent survival time for both regimens to elucidate the role of doxorubicin in their retrieval. Results: Sixty-four of the 173 randomly assigned patients had an event. Of these, 55 experienced progression or recurrence after initial treatment. Eleven (31%) of 36 patients treated with CFV were successfully retrieved with a doxorubicin-containing regimen and surgery and remain alive at last contact, whereas only one (6%) of 18 patients treated with CD was alive after retrieval therapy. Conclusion: CFV is effective for stage I or II HB. Doxorubicin can be omitted as part of initial therapy in the majority of these patients, potentially limiting the long-term cardiac toxicities, without compromising outcome. Doxorubicin is effective in rescuing patients with recurrent disease after CFV and should be incorporated as a means of intensifying initial therapy for advanced-stage, nonmetastatic HB. Outcome of patients with metastatic disease at diagnosis is poor, and improving their survival will require new therapeutic approaches.

AB - Purpose: Systemic chemotherapy has improved the survival of patients with hepatoblastoma (HB). INT-0098 Intergroup Liver Tumor Study demonstrated that patients with HB treated with either cisplatin/fluorouracil/vincristine (CFV) or cisplatin/doxorubicin (CD) had a similar survival. The Children's Oncology Group adopted the less toxic CFV as the standard regimen for treating HB. However, international cooperative groups still favor the CD combination. We therefore decided to revisit the role of doxorubicin for the treatment of HB. Methods: Outcomes of patients with HB on the INT-0098 study were reviewed with an emphasis on the postevent survival time for both regimens to elucidate the role of doxorubicin in their retrieval. Results: Sixty-four of the 173 randomly assigned patients had an event. Of these, 55 experienced progression or recurrence after initial treatment. Eleven (31%) of 36 patients treated with CFV were successfully retrieved with a doxorubicin-containing regimen and surgery and remain alive at last contact, whereas only one (6%) of 18 patients treated with CD was alive after retrieval therapy. Conclusion: CFV is effective for stage I or II HB. Doxorubicin can be omitted as part of initial therapy in the majority of these patients, potentially limiting the long-term cardiac toxicities, without compromising outcome. Doxorubicin is effective in rescuing patients with recurrent disease after CFV and should be incorporated as a means of intensifying initial therapy for advanced-stage, nonmetastatic HB. Outcome of patients with metastatic disease at diagnosis is poor, and improving their survival will require new therapeutic approaches.

UR - http://www.scopus.com/inward/record.url?scp=44249119869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44249119869&partnerID=8YFLogxK

U2 - 10.1200/JCO.2006.09.7204

DO - 10.1200/JCO.2006.09.7204

M3 - Article

C2 - 18467729

AN - SCOPUS:44249119869

VL - 26

SP - 2379

EP - 2383

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 14

ER -